ClinicalTrials.gov
public full text
Public Domain
Atrasentan in Treating Patients With Prostate Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase III trial to determine the effectiveness of atrasentan in treating patients who have prostate cancer that has not responded to hormone therapy.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer#1112049
- Atrasentan in Treating Patients With Progressive or Recurrent Malignant Glioma#916960
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)#1030137
- Hormone Therapy in Treating Patients With Rising PSA Levels Following Radiation Therapy for Prostate Cancer#1323498
- Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia#912372
Record · ID 1309769
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive